Abstract
The enhancement of nasal insulin absorption by sodium taurodihydrofusidate (STDHF) was studied in rabbits and rats. Using identical nasal formulations remarkable interspecies differences were observed. The fusidate derivative at 1% (w/v) enhanced nasal insulin bioavailability from 0.9 to 5.2% and from 0.3 to 18.0% in rabbits and rats, respectively. In both species the insulin formulations with STDHF resulted in strong hypoglycemic responses. Coadministration with the trypsin inhibitor aprotinin tended further to increase insulin bioavailability in rats and decrease insulin bioavailability in rabbits; however, these aprotinin effects were not statistically significant. Addition of the aminopeptidase inhibitor bacitracin to the STDHF containing formulation did not have any effect on insulin bioavailability in rats. Hence, STDHF is a potent enhancer of nasal insulin absorption, probably both by facilitating insulin transport through the nasal mucosa and possibly also by inhibiting enzymatic degradation. Further, interspecies differences and, experimental animal conditions can greatly affect nasal drug absorption.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Y. W. Chien and S. F. Chang. In Y. W. Chien (ed.), Transnasal Systemic Medications, Elsevier, Amsterdam, 1985, pp. 1–99.
S. Hirai, T. Yashiki, and H. Mima. Int. J. Pharm. 9:165–172 (1981).
S. Hirai, T. Yashiki, and H. Mima. Int. J. Pharm. 9:173–184 (1981).
K. Morimoto, K. Morisaka, and A. Kamada. J. Pharm. Pharmacol. 37:134–136 (1984).
S. Hirai, T. Ikenaga, and T. Matsuzawa. Diabetes 27:296–299 (1978).
T. Nagai, Y. Nishimoto, N. Nambu, Y. Suzuki, and K. Sekine. J. Control. Rel. 1:15–22 (1984).
J. P. Longenecker, A. C. Moses, J. S. Flier, R. D. Silver, M. C. Carey, and E. J. Dubovi. J. Pharm. Sci. 76:351–355 (1987).
A. N. Fisher, K. Brown, S. S. Davis, G. D. Parr, and D. A. Smith. J. Pharm. Pharmacol. 37:38–41 (1985).
S. Hirai, T. Yashiki, T. Matsuzawa, and H. Mima. Int. J. Pharm. 7:317–325 (1981).
V. H. L. Lee, D. Gallardo, and J. P. Longenecker. Proc. Int. Symp. Control. Rel. Bioact. Mater. 14:55–56 (1987).
B. J. Aungst and N. J. Rogers. Pharm. Res. 5:305–308 (1988).
L. Illum, N. Farraj, H. Critchley, and S. S. Davis. Int. J. Pharm. 46:261–265 (1988).
E. Björk and P. Edman. Int. J. Pharm. 47:233–238 (1988).
J. T. Young. In C. S. Barrow (ed.). Toxicology of the Nasal Passages, Hemisphere, Washington, D.C., 1986, pp. 27–36.
J. G. Hardy, S. W. Lee, and C. G. Wilson. J. Pharm. Pharmacol. 37:294–297 (1985).
K. S. E. Su. Pharm. Int. 1:8–11 (1986).
A. S. Harris, J. M. Nilsson, Z. G. Wagner, and U. Alkner. J. Pharm. Sci. 75:1085–1088 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Deurloo, M.J.M., Hermens, W.A.J.J., Romeyn, S.G. et al. Absorption Enhancement of Intranasally Administered Insulin by Sodium Taurodihydrofusidate (STDHF) in Rabbits and Rats. Pharm Res 6, 853–856 (1989). https://doi.org/10.1023/A:1015904404442
Issue Date:
DOI: https://doi.org/10.1023/A:1015904404442